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ABSTRACT 
Heterosexual HIV transmission is the most common viral transmission route, worldwide, 
where young women are more susceptible to HIV infection than men. To establish a 
persistent infection the virus needs to cross the mucosal surface of the female genital tract 
(FGT). The FGT mucosa is thus considered to be the portal of HIV entry and initial site of 
viral replication. A better understanding of the immunological milieu at the portal of viral 
entry is crucial for the development of preventive interventions. Hence, in this thesis we 
quantified and characterized immune cells, primarily subsets of CD8+ T cell, in the FGT 
tissues of HIV-infected and uninfected women. 
In Paper I and II, we observed that HIV-infected women displayed similar levels of 
CD4 expression in their ectocervix as compared to uninfected controls. However, they 
showed higher immune activation levels as well as signs of HIV replication in their cervix. 
An inflammatory environment in the genital mucosa may promote viral replication and 
genital shedding and thereby increase the risk of sexual HIV transmission. The HIV-infected 
women also had elevated levels of cervical CD8+ cells, which correlated significantly with 
cervical viral load. The CD8+ cells were predominantly intraepithelial CD8+ T cells and 60% 
of them expressed CD103 (Paper II, III). Our data thus suggests that CD8+ T cells, including 
tissue-resident CD8+ T cells, may be actively recruited to/or expanded in the genital mucosa 
of chronically HIV-infected sex workers. This implies that tissue-residing CD8+ T cells play 
an important role in local HIV pathogenesis. To further investigate immune responses in the 
FGT mucosa we assessed the expression of MAIT cells in the genital tissues of healthy 
women (Paper IV). FGT-derived MAIT cells preferentially localized in the ectocervical 
epithelium and were biased towards IL-17 and IL-22 production upon bacterial stimulation. 
This indicates that functional MAIT cells localized near the luminal surface of the genital 
mucosa may be important for the preservation of the genital barrier integrity and may act as a 
first line of defence against invading pathogens.  
In summary, this thesis describes the localization and distribution of immune cells in the 
genital mucosa of HIV-infected and uninfected women. Studies described here may 
contribute to the knowledge needed for development of vaccination and/or microbicide 
strategies against HIV and other sexually transmitted infections. 
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1 INTRODUCTION 
 
1.1. The human immunodeficiency virus (HIV) 
 
The year 1981 is generally referred to as the beginning of the human immunodeficiency virus 
type 1 (HIV-1) epidemic. In 1981, the Centre for Disease Control reported about five, 
previously healthy, homosexual men who had developed Pneumocystis pneumonia, a disease 
normally associated with severe immunosuppression.1 Shortly after, other cases of rare 
opportunistic diseases together with symptoms including fever and weight loss become 
evident, particularly in homosexual men.2,3 The unknown disease emerging in these 
individuals was characterized by severe immunosuppression, and it was therefore named 
acquired immunodeficiency syndrome (AIDS).4 In 1983, a group of French scientists 
identified the causative agent of AIDS to be a virus that was later named HIV-1.5 After the 
discovery of HIV-1, a second type of the virus (HIV-2) was isolated from AIDS patients 
originated from West Africa.6 However, it is HIV-1 that is almost entirely responsible for 
the HIV epidemic worldwide and it will hence be discussed in this thesis and referred to as 
HIV unless otherwise stated. 
HIV originates from the related Simian Immunodeficiency virus (SIV), which infects non-
human primates (NHP).7,8 The outcome of the SIV disease progression varies in the natural 
(sooty mangabeys, African green monkeys and others) and non-natural hosts (such as 
monkeys of Asian origin). Namely, the natural SIV-infected hosts do not develop a clinical 
disease (e.g. these monkeys resemble an AIDS-resistant phenotype), while in the non-natural 
hosts, SIV infection causes a disease similar to human AIDS.9 The SIV-infected NHP 
provide a valuable animal model to study HIV related pathogenesis and evaluate diverse 
prophylactic and therapeutic approaches.  
 
1.1.2. HIV viral structure and life cycle 
 
HIV can be spread by sexual contact, from infected mother to her child and as a blood-borne 
infection. HIV is a member of the genus Lentivirus and belongs to the family of retroviruses 
(Retroviridae). Like other lentiviruses, HIV is capable of establishing a long-term slowly 
progressive disease. HIV is an enveloped virus containing two copies of positive-stranded 
ribonucleic acid (RNA), packaged within a core of viral proteins. The HIV RNA genome is 
about 9.2 kb and consists of long terminal repeats and genes encoding for structural proteins 
(gag), envelope glycoproteins (env), viral enzymes (pol), regulatory proteins (tat, rev) and 
accessory proteins (vif, nef, vpr, vpu). 
HIV target cell entry occurs through the viral envelop protein gp120, which interacts with the 
major receptor cluster of differentiation (CD)4 and with one of the two co-receptors (CC 
chemokine receptor (CCR)5 and CXC chemokine receptor (CXCR)4) (Figure 1). However, 
the majority of initial HIV transmissions occur in a CCR5 dependent manner.10 Moreover, 
Caucasian individuals who have a 32 base pair deletion within the CCR5 gene (CCR532) 
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display a protective phenotype against HIV infection,11 indicating that the CCR5 co-receptor 
plays a crucial role for the establishment of the viral infection. After successful entry, viral 
material is released into the host cell where the reverse transcriptase transcribes one of the 
viral RNA copies into a double-stranded deoxyribonucleic acid (DNA) that is further 
transported into the nucleus. At the same time, the viral enzyme integrase enters the nucleus 
and initiates the integration of viral DNA into the host cell genome. The integrated viral DNA 
can remain transcriptionally silent for many years and thereby establish viral latency. Upon 
active transcription, the viral mRNA is subsequently translated near the endoplasmic 
reticulum. Newly synthesized viral proteins are further assembled into a viral particle and 
released by budding from the cellular membrane. 
HIV displays a great replicative capacity. It has been estimated that up to 108 cells can be 
infected, and more than 1010 viral particles can be produced daily.12,13 Moreover, HIV 
replication is associated with a high mutation rate that enables the virus to evade immune 
responses, develop resistance to pharmacological treatments, and makes it difficult to develop 
an effective vaccine.  
 
 
 
Figure 1. HIV life cycle. Schematic picture showing that HIV goes through multiple steps (Binding 
and Fusion; Reverse Transcription; Transcription; Assembly; Budding and Maturation) to 
reproduce itself and create more virus particles. Reprinted with permission.14 
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1.2. Global HIV distribution 
 
By the end of 2014, around 40 million people were reported to be HIV infected. During 2014 
about 2 million people became newly infected with HIV and around 1.2 million people died 
from AIDS related illnesses.15 African countries bear the burden of the HIV epidemic, with 
heterosexual transmission being the most prevalent mode of HIV transmission (discussed 
below). Sub-Saharan Africa is considered to be the most affected region, with 66% of new 
HIV infections, globally, occurring in this region. In 2014, there were recorded 25.8 million 
people living with HIV in Sub-Saharan Africa and more than 70% of adults living in this 
region have never been tested for HIV.15,16 The rate of new HIV infections has increased by 
26% in the Middle East and North African region during the past 14-15 years. Alarming facts 
are furthermore coming from Eastern Europe and Central Asia with 140.000 new infections 
were estimated in 2014, which was 30% higher as compared to year 2000.15 
Despite the availability of antiretroviral therapy (ART) and comprehensive public health 
measures, HIV transmission in the European region has not been drastically declining. In 
Western Europe, sex between men is the predominant mode of HIV transmission in contrast 
to Eastern Europe where transmission through drug injections and heterosexual transmission 
are the most common transmission routes.17 
 
1.2.1. HIV prevalence among key populations: female sex workers 
 
It is evident that HIV prevalence among sex workers is 12 times higher than among the 
general population.18 
In Kenya, HIV prevalence among the general population is around 6%. However, among key 
populations, such as men who have sex with men and female sex workers (FSW), HIV 
prevalence is considerably higher. FSW have the highest reported HIV prevalence (30%) 
among other groups in Kenya.19 Furthermore, it has been shown that about 50% of HIV-
positive FSW are unaware of their HIV infection. As a consequence, FSW continue to pose 
high risk of HIV transmission as well as experience delays in access to treatment and 
healthcare.20 Despite high ART coverage among the general Kenyan population, with >80% 
of ART-eligible people on treatment, only about 20-30% of HIV-infected FSW are receiving 
ART.19,21 
Unprotected sex, sexual violence, discrimination as well as social and economic factors are 
associated with the increased vulnerability to HIV transmission in this group.18 It is suggested 
that elimination of sexual violence alone could prevent 17% of HIV infections in FSW and 
their clients. Moreover, decriminalization of the sex work could avert 33% of HIV infections 
in FSW and their clients in the next decade.21 This indicates that assessment of the issues 
present in key populations together with legal measures may reduce HIV transmission in 
these groups and subsequently overall HIV transmission. 
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1.2.2. HIV today 
 
The introduction of ART can truly be considered as one of the major achievements on the 
way of defeating the HIV epidemic. The introduction of ART has changed the perception of 
HIV as a deadly disease to a manageable chronic condition. When ART was shown to reduce 
HIV transmission,22 HIV treatment or Pre-Exposure Prophylaxis (PrEP) was implemented as 
a prevention measure for individuals at high risk of HIV infection.23 Today, new ambitious 
treatment goals are set to end the HIV epidemic. To achieve the 90-90-90 treatment target by 
year 2020, i.e. 90% of people living with HIV will know their HIV status, 90% of people 
living with HIV who know their status will receive ART, and 90% of people on treatment 
will have suppressed viral loads (90-90-90). And most importantly, to reach the ultimate goal 
of ending the HIV epidemic by year 2030.24  
In 2001, only 1 million people living with HIV had access to ART, but in 2015, more that 15 
million people received antiviral treatment. Because of wide ART coverage the annual new 
infections dropped from 3.1 to 2 million, and the number of AIDS related deaths has dropped 
from 2 to 1.2 million in the past 15 years. However, as more individuals are gaining access to 
ART, the total cost increases, making wide ART access a big economical challenge. 
According to the UNAIDS estimates, $31.1 billion will be required for the AIDS response in 
year 2020.16 Moreover, other issues associated with ART, including side effects, antiviral 
drug resistance and sub-optimal antiviral drug penetration in viral reservoirs, remain 
unresolved.25,26 
 
1.3. The immunopathogenesis caused by HIV infection 
 
As a virus that causes immunodeficiency syndrome, HIV infection deteriorates virtually all 
components of the immune system. HIV associated alterations are especially pronounced in 
the T cell compartment and result in increased activation of the immune system. 
 
1.3.1. CD4+ T cells 
 
Progressive CD4+ T cell depletion is a clinical manifestation of HIV infection and CD4+ T 
cell count is the most common marker used for monitoring the progression of HIV disease. 
CD4+ T cells are the preferential target cells for HIV infection and hence these cells are 
primarily affected by HIV pathogenesis. The initial CD4+ T cell destruction occurs due to the 
direct cytopathic effects caused by the virus.27 During the early phase of HIV infection, 
massive depletion of CD4+ T cells occurs in mucosal compartments (mainly in the 
gastrointestinal mucosa) as well as in peripheral blood and lymph nodes.28 Likewise, the 
depletion of cervical CD4+ T cells is observed in early HIV infection.29 A progressive CD4+ T 
cell homeostatic failure, mediated by the virus itself, and together with the high immune 
activation ultimately leads to the cell depletion over time.27 Dramatically low levels of CD4+ 
T cells, <200 cells/mm3, are associated with HIV progression to AIDS.  
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While early ART initiation effectively restores the CD4+ T cell levels, they do not reach the 
same magnitude as present in HIV-uninfected individuals.30 
Additionally, latently infected resting memory CD4+ T cells constitute the main viral 
reservoir, in both ART- treated and treatment naïve patients,31 and this is considered to be one 
of the major obstacles for successful HIV eradication.32  
 
1.3.2. CD8+ T cells 
 
While the increased magnitude of HIV-specific CD8+ T cell responses is associated with the 
drop of acute viremia, already during the early stage of the infection these cells become 
inefficient and lose their ability to efficiently control HIV replication.33 The expansion of the 
HIV-specific CD8+ T cell pool peaks at median of 250 days post infection and remains 
elevated during the course of the infection.34,35 However, the HIV-specific CD8+ T cells 
represent less than 10% of the total CD8+ T cell pool, with the rest accounting for reactivated 
responses to latent pathogens, such as herpes viruses, and bystander activated CD8+ T cells.35 
Moreover, both HIV-specific and bulk CD8+ T cells display a highly activated phenotype, 
which is often defined by the upregulation of CD38 and human leukocyte antigen (HLA)-DR 
molecules.36,37 Particular expansion of CD38 and HLA-DR expressing CD8+ T cells has been 
shown to be associated with decreased levels of CD4+ T cells and progression of AIDS.36 
Persistent antigenic exposure subsequently leads to the exhaustion of CD8+ T cells and 
progressive loss of their functions.35 Expression of exhaustion markers, such as programmed 
death-1 (PD-1), and inhibitory molecules on HIV-specific CD8+ T cells is associated with 
poor polyfunctionality of these cells and positively correlates with the plasma viral load 
(PVL).38-40 Moreover, HIV-specific CD8+ T cells isolated from blood of chronic HIV-
infected patients have been shown to display poor cytolytic capacity.41 T-box transcription 
factors T-bet and Eomesodermin (Eomes) are transcription factors that have a crucial role in 
regulating the effector and memory differentiation of CD8+ T cells.42 Imbalance between the 
T-bet and Eomes expression in HIV-specific CD8+ T cells (T-betdimEomeshigh) has been 
associated with elevated expression of inhibitory molecules, poor polyfunctionality and 
decreased expression of Granzyme B as compared to corresponding T cells expressing higher 
levels of T-bet and lower levels of Eomes.40 Concurrently, in HIV- infected individuals, 
CD8+ T cells accumulate within the intermediate memory pool and exhibit a skewed 
maturation phenotype.43 Altogether this suggests that expansion of activated/exhausted early 
differentiated and poorly functional HIV-specific CD8+ T cells fails to control the viral 
replication. Furthermore, even the administration of ART fails to completely restore the 
elevated CD8+ T cell numbers, thus resulting in a low CD4/CD8 ratio in HIV-infected 
individuals.44 Low CD4/CD8 ratio has been observed in ART-treated individuals 
experiencing AIDS unrelated morbidities,45 suggesting that despite the effective treatment, 
the immunological imbalance may lead to the non-AIDS related adverse clinical events.  
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1.3.3. Immune activation 
 
Immune activation and inflammation is a hallmark of HIV infection. Levels of immune 
activation are directly associated and predictive of HIV disease progression.36,46 Apart from 
the highly activated T cells, HIV pathogenesis also induces activation of B cells and of cells 
belonging to the innate immune system.47,48 Furthermore, elevated levels of proinflammatory 
cytokines such as type-1 interferons (IFN), tumour necrosis factor (TNF)α, interleukin (IL) 
1β and IL-6 are observed in circulation and mucosal compartments of HIV-infected 
individuals.46,49 HIV pathogenesis is also associated with disruption of barrier integrity in 
mucosal tissues.50,51 Compromised integrity of the mucosal barrier in the intestinal tract 
(“leaky gut”) subsequently leads to the translocation of the microbial products from the gut 
into the circulation. Increased levels of plasma Lipopolysaccharides (LPS), a surrogate 
marker of microbial translocation, directly correlates with the activated state of the immune 
system.52  
Moreover, persistent immune activation is likely to cause a systemic ageing of physiological 
functions.46 Namely, HIV infected individuals present similarities with individuals of old age, 
and more often experience age-related diseases compared to age-matched uninfected adults.53 
Altered physiological functions and immunological abnormalities persist even after the ART 
treatment,53 indicating that even treated HIV-infected individuals do not fully restore back to 
good general health conditions. 
 
1.4. Heterosexual HIV transmission 
 
The majority of all HIV transmissions, worldwide, occur through heterosexual transmission, 
where young women are twice as likely to become infected with HIV as compared to men.54 
Women represent about half of all people living with HIV, and while the incidence of HIV is 
declining globally, its impact disproportionally concerns young women. According to the 
2015 UNAIDS report, the majority of newly HIV-infected are represented by young women; 
e.g. about 62% among 15-19 years old, and 56% among 15-24 years old.16 This 
“feminization” of the HIV epidemic is particularly pronounced in Sub-Saharan Africa where 
women account for two out of three new HIV infections.55 
All sexual transmissions occur across a mucosal surface and the genital mucosa is therefore 
considered to be the portal of viral entry and the first site where HIV replication occurs. 
However, the efficiency of vaginal male- to- female HIV-1 transmission is low, about 0.08-
0.3 % per unprotected sexual intercourse,56 which indicates the effectiveness of the genital 
barrier against HIV. Recent data indicate that establishment of viral infection via the 
heterosexual mode of transmission is associated with genetic background of the transmitted 
virus, that favours increased viral fitness. Furthermore, selection bias of the transmitted virus 
is lower in a more permissive environment, e.g. presence of the genital inflammation, but also 
in the virus transmitted to women, compared to men, suggesting a more permissive 
environment in the female genital mucosa.57 
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1.5. The female genital tract  
 
The female genital tract (FGT) consists of different compartments, responsible for two major 
tasks, providing a protection against invading pathogens and at the same time creating a 
tolerogenic environment for semi-allogenic fetus.55,58 The FGT can be divided in distinct 
anatomical regions; upper (ovaries, fallopian tubes, uterus) and lower (cervix and vagina) 
FGT (Figure 2). The mucosa of the uterus (endometrium) consists of a monolayer of 
columnar epithelial cells, and undergo major structural and functional changes during the 
course of the menstrual cycle.55  
 
 
 
 
Figure 2. Schematic representation of the female genital tract. A) Single layer of the columnar 
epithelium in the endometrium and endocervix. B) Transformation zone between the endo- and the 
etcocervix. C) Multilayer squamous epithelium in the ectocervix and vagina. D) Distribution of tight 
junction proteins within the multilayered epithelium. E) Distribution of CD4+ cells (brown) in the I.) 
epithelial and II.) submucosal compartments of the ectocervix. The ectocervical tissue section was 
counterstained with hematoxylin (blue) to visualise all cells. 
 
The cervical cavity (endocervix) connecting the uterus and vagina is covered by a single-
layer of the simple columnar epithelial cells that produce endocervical mucus, providing an 
additional physical and antimicrobial barrier.59,60 The intravaginal portion of the cervix is 
called ectocervix and it is, just like the vagina, lined by a thick multilayer squamous 
epithelium. Intact ectocervical and vaginal epithelium provides a robust physical barrier, 
which harbours numerous immune cells and tight junction proteins.61-63  
The transition area between the endo- and the etcocervix, where the epithelium transforms 
from a single- to a multilayer, is called the transformation zone. This area is characterized by 
a particular abundance of immune cells (including HIV target cells) in a relatively small area, 
as compared to the rest of the FGT, suggesting an increased vulnerability at this site.55,64  
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1.5.1. HIV target cells in the genital mucosa 
 
HIV transmission can occur through the mucosal barriers in both the upper and the lower 
FGT.65 However, the vaginal and the ectocervical mucosa display a larger surface area and 
are thus likely to be the primary sites to encounter transmitted virus during sexual 
intercourse61,65 (Figure 3). CD4+ T cells have been shown, in both NHP models and in 
cervical ex vivo explant models, to be the primary target cells for HIV infection.66,67 CD4+ T 
cells are abundant in ectocervical mucosa where they are dispersed in the epithelium and the 
underlying submucosa.68 Recent studies indicate that FGT-derived IL-17 producing CD4+ T 
cells (Th17) as well as α4β7- and α4β1 integrin expressing CD4+ T cells are relatively more 
susceptible to HIV infection as compared to other CD4+ T cell subsets.69,70 Furthermore, 
cervical Th17 cell are depleted early during the HIV infection, supporting the finding of the 
preferential infection of these cells.29 
Additionally, other cell types, including CD4 and CCR5 expressing dendritic cells (DCs) and 
macrophages, which are present in the female genital mucosa, are implicated in HIV 
susceptibility and transmission.71,72 Ex vivo studies in cervical explant models have shown 
that HIV virions can penetrate up to 50μm of the intact ectocervical epithelium.73 Langerhans 
cells, a subset of DCs, residing in the ectocervical epithelium, are likely to be among the first 
cells to encounter virus and they can further pass the infectious virions to susceptible CD4+ T 
cells.68,74 They can either bind HIV through Langerin or via the CD4/CCR5 receptor 
complex.75 Furthermore, submucosal DCs are also susceptible to HIV infection and can thus 
also facilitate CD4+ T cell infection, through the C-type lectin receptors, DC-specific ICAM-3 
grabbing non-integrin (DC-SIGN) and mannose receptor (MR), and their interactions with 
gp120.76-78 CD4+CCR5+ macrophages are another cell population of HIV target cells that 
reside in the female genital mucosa and have been shown to be productively infected by HIV 
ex vivo.79 After the establishment of the small focally infected population, also called 
“founder population”, the virus then disseminates to secondary lymphoid organs, which 
subsequently leads to systemic infection. 
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Figure 3. Schematic representation of the suggested mechanism for HIV heterosexual 
transmission across the female genital mucosa. The cervix and vagina are covered by a 
multilayered epithelium harboring HIV target and effector cells, as well as epithelial tight junction 
proteins, which are protecting against invading pathogens like HIV. The epithelial linings are covered 
by genital secretions containing hormones, microbes and innate proteins that also play an important 
role in HIV transmission. Microlesions in the epithelium are thought to facilitate entrance of HIV. 
 
Despite the abundance of susceptible target cells in the female genital mucosa, the initial 
transmission events are associated with a relatively small founder population of infected cells. 
Only 40-50 SIV RNA+ cells have been detected in the endocervical mucosa after 3-4 days of 
SIV infection in NHP.66,80,81 Deep sequencing has furthermore revealed that in about 80% of 
cases of heterosexual HIV transmission, the initial infection is established by single virus 
genotype in a CCR5 dependent manner.10 Given the small size of the genetically 
homogeneous founder population, these initial events of HIV transmission represent great 
vulnerability of the virus and may therefore provide a good window of opportunity for 
preventive interventions (Figure 4).  
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Figure 4. Window of opportunity. A schematic picture showing changes in the levels of SIV RNA 
in the FGT upon experimental SIV infection. The “window of opportunity” represents vulnerability of 
the virus and thus provides an opportunity for potential interventions. Adapted with permission.82 
 
1.5.2. Mucosal inflammation and immune activation 
 
The strongest predictor of HIV transmission risk through sexual intercourse is viral load in 
blood and genital secretions of the HIV-infected partner.83 Additionally, number of factors 
associated with inflammation and activation in the genital mucosa has been shown to 
subsequently increase sexual HIV transmission. Sexual activity per se as well as exposure to 
seminal fluid is associated with local inflammation and migration of activated lymphocytes to 
the genital tissues.84 Elevated numbers of T cells, DCs and macrophages as well as higher 
levels of proinflammatory cytokines have been seen in the ectocervical tissues of women 
having unprotected sexual intercourse.85 Presence of sexually transmitted infections (STIs), 
including, Herpes simplex virus (HSV)2, N. gonorrhoeae, Chlamydia trichomonas among 
others, contribute to a proinflammatory milieu in the genital mucosa and these STIs have also 
been associated with increased risk of HIV acquisition and transmission.86-88 
Moreover, alterations in the local microflora of the FGT have also been associated with HIV 
susceptibility. While the dominance of Lactobacillus species in the genital microflora has 
been associated with lower HIV prevalence, dysbiotic women with clinical Bacterial 
vaginosis (BV) are at higher risk of HIV acquisition.89,90 Presence of BV in the genital 
mucosa is associated with reduced levels of factors involved in mucosal barrier integrity as 
well as elevated levels of inflammatory cytokines, which may partially explain why BV 
contributes to increased HIV acquisition.84  
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Hormonal status has a great impact on the immunological environment in the FGT mucosa 
and thus, sex hormones and the menstrual cycle are believed to play a role in HIV 
susceptibility.55 The progesterone-dominated luteal phase, rather than follicular phase, has 
been related to increased SIV transmission in NHP.91 Moreover, use of Depo-Provera, an 
injectable progesterone-based hormonal contraceptive, is associated with elevated levels of 
genital proinflammatory cytokines and increased risk of HIV of acquisition.87,92 
Conversely, low immune activation or a so-called “immune quiescent” state in the genital 
mucosa has been observed in HIV-exposed seronegative (HESN) individuals, who display a 
semi-resistant phenotype against HIV infection.93 These HESN individuals are found in 
different cohorts, including HIV-seronegative commercial female sex workers from the 
Pumwani cohort, established in Nairobi, Kenya.94 These individuals will be further discussed 
in this thesis and referred to as HIV-seronegative female sex workers (HIV-FSW). 
Overall, the inflammatory environment and influx of HIV target cells to the genital mucosa 
can contribute to a higher risk of HIV acquisition as well as spark local viral replication and 
increase the transmission risk upon an ongoing infection. 
 
1.6. Mucosal immune responses to HIV 
 
1.6.1. Innate immunity 
 
Innate immune responses represent the first line of defence and are often referred to as “non-
specific immunity”. Components of the innate immunity provide rapid defence and usually 
act within hours upon encounter with the antigen. Moreover, production of chemokines and 
proinflammatory cytokines by innate cells, results in recruitment and activation of cells 
belonging to the adaptive, or the so-called “specific immunity”.95 
Recognition of foreign antigens by innate immune cells occurs through the pattern 
recognition receptors (PRRs). Various PRRs, including Toll-like receptors (TLRs) expressed 
on innate immune cells can trigger inflammatory cascade resulting in induction of an antiviral 
environment through the release of proinflammatory cytokines.95 A recent study by Yao et al. 
propose that early antiviral innate responses in the genital mucosa of HIV-FSW individuals 
may be an important correlate of the HIV-FSW semi-resistant phenotype.96 Yao and 
colleagues suggest that elevated levels of epithelial TLRs 3 and 7 may limit early HIV 
infection by sensing viral dsRNA and ssRNA at the portal of entry, while other immune 
receptors are downregulated to minimize inflammatory responses.  
Additionally, mucosal surfaces are rich in diverse components belonging to the innate 
immune system. Soluble components of the innate immunity, including mucins, 
antiproteases, and antimicrobial peptides possess antimicrobial activity and are scattered 
within the FGT.97,98 For example, serine protease inhibitors (i.e. serpins and elafin) display in 
vitro anti-HIV activity and they are associated with relative HIV resistance in the genital 
mucosa of HIV-FSW individuals.97-99 Extensively studied host cells restriction factors 
including Apolipoprotein B mRNA editing enzyme catalytic, polypeptide like 3 (APOBEC 3) 
protein, Tripartite Motif (TRIM)5α, tetherin and others can interfere with viral replication in 
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infected cells, however HIV has developed several mechanisms to abolish their anti-viral 
activity.100 
Natural killer (NK) cells are innate immune effector cells with a potent cytolytic potential. 
NK cells are present in all genital tissues, however they are more predominant in the upper, 
as compared to the lower FGT.55,101 NK cells are suggested to mediate early control of HIV 
infection102 and studies from several HESN cohorts, including African FSW cohorts, have 
shown an association between the functional NK cells responses in circulation and protection 
against HIV infection.103,104 It is however unclear whether the NK cell-mediated responses in 
the FGT mucosa are reflective of the HIV resistant phenotype.  
Apart from establishing rapid antiviral immune responses, the innate immune cells also 
activate adaptive immune responses.95 DCs together with other antigen presenting cells 
(APCs), (e.g. macrophages and B cells), take up and process antigens and thereafter migrate 
to nearby secondary lymphoid organs. Once in the lymphoid compartments, APCs present 
foreign antigenic peptides to naïve CD4+ and CD8+ T cells in major histocompatibility 
complex (MHC) class I and II dependent manner, respectively. Antigen-experienced T cells 
acquire an effector phenotype and can then migrate to the site of infection.100  
 
1.6.2. MAIT cells 
 
Mucosal-associated invariant T cells (MAIT) are a recently described innate-like T cell 
population, which is present in various mucosal compartments as well as in liver and 
peripheral blood.105-107 Human MAIT cells express a semi-invariant T cell receptor (TCR), 
including Vα7.2 coupled with restricted Jα segments and limited Vβ repertoires, as well as 
high levels of C-type lectin CD161 and the interleukin (IL)-18 receptor α-subunit (IL-
18Rα).106,108-110 In contrast to conventional T cells, MAIT cells recognize microbial B2 
vitamin metabolites presented via the evolutionarily conserved MHC I-related (MR) 1 
molecule.105,110-112 Additionally, some studies indicate that MAIT cells can be activated in 
presence of inflammatory and homeostatic cytokines, including IL-7, IL-12, IL-15 and IL-18 
in an antigen and MR1-independent fashion.113-116 Mature MAIT cells display a distinct 
transcriptional profile, expressing both classical effector T cell transcription factors T-bet and 
Eomes, as well as promyelocytic leukemia zinc finger (PLZF) and retinoic acid-related 
orphan receptor γt (RORγt) transcription factors.106,107,113 This transcriptional phenotype 
justifies the ability of MAIT cells to produce various cytokines, including IFN-, TNF, IL-17, 
and IL-22.107,110,117 Mature MAIT cells exhibit effector memory phenotype and possess high 
cytolytic capacity. It has been shown that human MAIT cells can kill Escherichia coli (E.coli) 
infected APCs as well as efficiently lyse Shigella flexneri infected epithelial cells.116,118 
Furthermore, Le Borhis and colleagues demonstrated that murine MAIT cells could respond 
to a variety of bacterial and fungal species and were protective against E. coli and 
Mycobacterium abscessus microbes.110 Likewise, human MAIT cells can also be activated by 
E.coli and are suggested to play a protective role in mycobacterial infections.110,119 
While it is suggested that MAIT cells do not become activated by viruses, functional 
impairment of circulating MAIT cells has however been observed in HIV-infected 
 13 
 
individuals.110,113 Furthermore, MAIT cells have been shown to be reduced in blood of HIV-
infected patients, however relatively preserved in their mucosal compartments.120,121 Thus 
suggesting that MAIT cells are affected by HIV. 
 
1.6.3. Humoral immunity 
 
The humoral immune responses belong to the arm of adaptive immunity, and primarily 
consist of immunoglobulin (Ig) secreting B cells. Humoral immune responses play a key role 
in the immune defence against a variety of pathogens, including HIV. Vaccine-induced 
broadly neutralizing antibodies protect NHP against infection with simian-human 
immunodeficiency virus.122 Moreover, polyfunctional non-neutralizing HIV-specific 
antibodies are present in circulation of HIV-seropositive individuals who control HIV 
replication (HIV-nonprogressors).123  
Whereas B cells represent a minor cell population within the FGT tissues, IgG and IgA –
producing plasma cells are still found in the genital mucosa. Despite the predominance of IgA 
in mucosal compartments, cervicovaginal secretions (CVS) are more abundant of IgG than of 
IgA, with IgG being partly derived from the circulation.55,124 Nevertheless, a recent report 
shows the presence of HIV-1 specific IgA in CVS of women participating in a microbicide 
trial and remaining HIV seronegative despite repeated exposure to HIV.125 Moreover, 
previous studies have shown the presence of HIV-neutralizing IgA in cervicovaginal lavage 
(CVL) of HIV-FSW, suggesting its association with a reduced risk of HIV acquisition.126 
Controversially, other data indicates minimal or absent IgA responses in CVL samples 
obtained from HESN individuals from different cohorts.127 The discrepancies in these studies 
highlight the necessity of further investigating mucosal correlates of protective humoral 
responses. 
 
1.6.4. Cell-mediated immunity 
 
Generally, cell-mediated immunity is a type of immunity mediated by T cells, classically 
involving CD4+ T helper cell responses and effector CD8+ T cell responses.100 CD4+ T helper 
cells are crucial for activation of other immune cells and particularly for helping B cells to 
produce antibodies. However, CD4+ T cells are highly susceptible to HIV infection and 
therefore mainly CD8+ T cell effector responses will be discussed here.  
A plethora of data indicates the importance of CD8+ T cell responses in controlling HIV 
infection.128 It was early observed that the appearance of HIV-specific cytotoxic CD8+ T 
cells, after onset of the acute HIV phase, correlated with the reduction of plasma viremia.129 
These findings were later confirmed in SIV-infected NHP, where intravenous administration 
of anti-CD8 antibodies resulted in increased viral replication in peripheral blood as well as 
lymphoid and non-lymphoid tissues.130 Additionally, highly polyfunctional and cytotoxic 
CD8+ T cells responses have been observed in blood and peripheral tissues of HIV-
nonprogressors from different cohorts.131-133 Distinct circulating CD8+ T cells responses have 
furthermore been observed in HESN individuals. HIV-specific CD8+ T cells from blood of 
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HIV-seronegative FSW from Puerto Rico had significantly lower CD38 surface expression 
than low risk controls, in consistence with an immune quiescent phenotype of HESN 
individuals.134 Kaul and colleagues have shown that the overall magnitude of circulating 
cytotoxic T-lymphocyte (CTL) responses was significantly lower in HIV-FSW as compared 
to HIV-infected women. However, CTL responses in HIV-FSW recognized different epitopes 
as compared to those targeted in HIV-infected women, suggesting that CTL responses differ 
rather qualitatively, than quantitatively in HIV-FSW.135 
Less is known about the association between the magnitude of CD8+ T cell responses in the 
female genital mucosa and protection against HIV infection. While the presence of cytotoxic 
CD8+ T cells in the cervix of HIV-infected women has been shown,136 these responses are 
suggested to be largely monofunctional and do not predict viral shedding.137  
Furthermore, HIV-specific CD8+ T cell responses observed in cervix do not correlate with 
those present in circulation in both treatment naïve and HIV-infected women receiving highly 
active antiretroviral therapy (HAART).138,139 This indicates that cervical CD8+ T cell 
responses are distinctly compartmentalized and are not predictable by their circulating 
counterparts.  
 
1.7. Tissue-residing T cells 
 
In non-chronic infections, after antigen clearance, host T cells retain the ability of “long-
term” memory, which upon repeated antigenic exposure results in a large magnitude of 
antigen-specific T cell responses. Generally, these memory T cell subsets are defined by their 
homing properties and anatomic distribution. Central-memory T (TCM) cells exhibit a great 
proliferation potential and express CCR7 and CD62L receptors, required for their 
recirculation through the secondary lymphoid tissues. In contrast, effector memory T (TEM) 
cells lack the constitutive CCR7/CD62L expression and instead express mucosa homing 
chemokine receptors and recirculate through blood and peripheral tissues. Moreover, TEM are 
characterized by possessing more immediate effector functions as compared to TCM.
140  
More recently, studies have identified another memory subset of T cells, having as good 
effector potential as TEM, although displaying a non-circulating phenotype and permanently 
residing within the peripheral tissues (TRM)
141 (Figure 5). TRM is a distinct memory 
population and display a unique transcriptional profile, which is different from the circulating 
memory T cells.142,143 TRM cells are found both in murine and human peripheral tissues where 
they preferentially localize within the epithelial compartments.144-146 Bona fide TRM cells can 
be defined by the expression of αE(CD103)β7 integrin together with CD69. CD103 
interaction with the tight junction protein E-cadherin mediates TRM cell retention within the 
epithelial compartment, while the CD69-mediated inhibition of sphingosine 1-phosphate 
receptor 1 hinders cell egress from the tissues.141 However, recent data indicates that even 
CD103- cells display a non-circulating TRM phenotype, suggesting involvement of other 
mechanisms providing TRM cell retention in tissues.
141,147 The formation and establishment of 
the TRM cell population are mediated by the local tissue environment, in the presence of TGF-
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β cytokine.142,147,148 CD8+ TRM cells have been more extensively characterized then CD4+ 
TRM, although the majority of TRM cells in human skin are CD4
+ T cells.147  
Different studies have shown that establishment of effector CD8+ TRM responses in peripheral 
sites upon vaccination is strongly associated with the control of viral infections, including 
Influenza, HSV and HPV.149-151 For example, the establishment of HSV-specific CD8+ TRM 
responses in the mice FGT mucosa, via recruitment of antigen-specific cells from circulation, 
fully protected these mice against lethal challenge with HSV-2.150 Moreover, in humans, 
vaccine-induced HPV responses have been shown to be more pronounced in cervical mucosa 
as compared to circulating counterparts.149 Hence, the sentinel role of tissue residing effector 
cells provides a front-line defence against invading pathogens at the tissue barriers. 
 
 
 
Figure 5. Schematic representation of distribution of different memory T cells. Upon antigenic 
stimulation, naïve T cells proliferate into effector T cells that migrate to the sites of infection. After the 
decline of effector phase, memory T cells recirculate through the different sites: TCM cells within the 
blood and secondary lymphoid organs, TEM between blood and non-lymphoid tissues, TRM are non-
circulating and are retained in the peripheral tissues. Reprinted with permission.152  
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2 AIM 
 
The main purpose of this thesis is to investigate the role of immune cells, with focus on CD8+ 
T cells, including tissue-resident CD8+ T cells and MAIT cells, in the FGT, the mucosal site 
of HIV exposure and replication. 
Specific aims: 
Paper I. To assess the expression of HIV target cells and levels of immune activation in the 
genital mucosa in HIV-infected versus uninfected women. 
Paper II. To enumerate and characterize cervical CD8+ T cells in HIV-infected and 
uninfected women in relation to viral load and local viral replication. 
Paper III. To enumerate and characterize CD103+CD8+ T cells in cervix and blood in HIV-
infected versus uninfected women.  
Paper IV. To characterize distribution and functional phenotype of MAIT cells present in the 
female genital mucosa and blood of healthy women. 
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3 MATERIALS AND METHODS 
 
3.1. Study populations and sample collection 
Samples from Kenyatta and St. Göran cohorts were used in Paper I, II, III, and Paper III, 
IV respectively.  
 
The Kenyatta cohort: HIV seropositive (HIV+) and seronegative (HIV-) female sex workers 
(FSW) were recruited through the Majengo Sex Worker Clinic. 94 HIV seronegative lower 
risk non-sex working women (HIV-LR) were recruited through a Maternal Health Clinic at 
the Pumwani Maternity Hospital.153 General inclusion criteria included age at least 18 years, 
uterus and cervix present, not actively menstruating, no symptomatic or clinically apparent 
cervical inflammation, willingness to undergo ectocervical biopsy collection and to abstain 
from vaginal sex during a healing period of two weeks. All study participants were within the 
same age range, were similarly distributed with regard to stages of the menstrual cycle, 
reported similar use of hormonal contraception, and similar numbers of pregnancies as well 
as sexual activity during menses. 
The HIV-infected women had been HIV infected for a median of 3 years, were ART-naïve 
and without prior history of AIDS-defining illnesses and acute health issues. Since HIV-
infected women were recruited from a sex-worker cohort, an additional group of HIV- FSW 
was recruited to control for presence of STIs and high-risk behaviour. All FSWs enrolled 
were active in sex work and were comparable in terms of condom use, HSV-2 
seropositivity, presence of other STIs and vaginal douching (insertion of water or water with 
soap in the vagina). The HIV+FSW included in this cohort have been followed for a median 
of 4 years (range 1-20) and HIV-FSW for a median of 7 years (range 3-19) at the date of 
sampling. It was furthermore established that FSW who remained HIV-seronegative despite 
high exposure rates, displayed a semi-resistant phenotype against HIV infection.94 Therefore 
phenotype alterations of these HIV-FSW may be partially reflected by this rare phenotype.  
Paired ectocervical tissue samples, CVS and peripheral blood samples were collected from all 
study participants and cryopreserved until required. 
 
The St. Göran cohort: Uterine tissue samples were obtained from Swedish women who 
underwent hysterectomy for nonmalignant and noninflammatory conditions (heavy menstrual 
bleeding and/or benign myoma) at the St. Göran Hospital, Stockholm. Exclusion criteria 
were: positivity to human papilloma virus (HPV), clinical symptoms of sexually transmitted 
infections during the 3 months prior to surgery and/or systemic immunosuppressive therapy. 
Fresh genital tissue samples were immediately transported to our laboratory. While the 
majority of the specimens were enzymatically digested into single cell suspension, one or two 
tissue blocks were snap-frozen immediately after dissection and cryopreserved at -80°C.  
 
Blood donors: Peripheral blood samples, used in Paper IV, were collected from healthy 
Swedish women who were in the same age range as the women who underwent 
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hysterectomy. Blood donors were recruited at the Blood Transfusion Clinic at the Karolinska 
University Hospital Huddinge, Stockholm. 
 
3.2. Ethical considerations 
All study participants were provided with written and oral information about the studies. 
Written informed consent was obtained from all individuals in accordance with the 
Declaration of Helsinki. All studies were reviewed and approved by the Regional Ethical 
Review Board of Stockholm. Additionally, studies I, II and III were approved by the research 
ethics boards at Kenyatta National Hospital (Nairobi, Kenya) and University of Manitoba 
(Winnipeg, Canada). Our collaborators from the University of Manitoba have been involved 
in research studies in the Nairobi area for nearly 30 years. They have established a strong 
community outreach program, including regular information meetings for study volunteers 
and program peer leaders. All participants were provided with HIV/STI prevention 
counseling, male and female condoms, family planning services, treatment of STIs, medical 
care for acute and chronic illnesses, access to adequate diagnostic testing and referral for 
specialist consultant and/or hospitalization at Kenyatta National Hospital if needed.  
In our studies we use ectocervical tissue biopsies obtained from the FSW. Hence, invasive 
sampling of the ectocervivical biopsies may raise concerns regarding the increased HIV 
susceptibility among sex workers. Therefore, all study participants, who underwent sampling 
procedure, were asked to abstain from vaginal sex for two weeks after the procedure and 
received monetary compensation equivalent to the expected lost income. Moreover, the 
cervical biopsy sampling method has been evaluated and considered to be a safe and well-
tolerated.154  
 
3.3. Methods 
 
3.3.1. Quantitative real-time PCR 
 
mRNA expression of the genes of interests in the ectocervical biopsies was assessed with 
quantitative real time PCR (qPCR) as described previously.155 RNA was extracted from the 
ectocervical biopsies, stored in RNAlater solution, with a commercially available RNeasy kit 
(Qiagen), according to the manufacturer’s protocol. RNA was further converted into 
complementary (c) DNA by reverse transcriptase enzyme. cDNA of the genes of interest 
(targets) was amplified, detected and quantified by the ABI PRISM 7700 system. 
Amplification of ubiquitin C (UBC) was used as an endogenous control. Ct values for target 
cDNA were normalized to UBC and fold change of the target genes was calculated as 2-dCT.  
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3.3.2. Cell isolation from tissues 
 
Genital tissue samples were collected by a pathologist immediately after the hysterectomy 
was performed and thereafter transported to our laboratory. Samples were maintained in ice-
cold medium supplemented with antibiotics and processed within 24 hours of surgery. Fresh 
genital tissue samples were dissected into distinct anatomical compartments and 
enzymatically digested into single cell suspension as previously described.156,157 At least 1 
cm2 of mucosa (approximately 500 mg wet weight) was used for downstream applications. 
Enzymatically digested tissues were further mechanically disrupted. Obtained cell 
suspensions were passed through a cell strainer and washed in phosphate-buffered saline 
(PBS).  
 
3.3.3. Flow Cytometry  
 
The immune phenotype of single cells was assessed by Flow Cytometry as previously 
described.37 The working principle of Flow cytometry is based on the “fluorescent antibody-
cell” complex differential reaction to light. In a stream of fluid, cells bound to the 
fluorescently labelled antibodies pass through a laser beam one at a time. Excited by the laser, 
these cells emit light at distinct wavelengths, allowing to assess their properties at the single 
cell level.  
Peripheral blood mononuclear cells (PBMCs) as well as mononuclear cells (MNCs) isolated 
from the genital tissues were labelled with monoclonal antibodies conjugated to fluorescent 
dyes, fixed and further acquired on the Flow Cytometer. In order to assess the expression of 
surface markers as well as cytokines and transcription factors, extracellular and intracellular 
antibody stainings were performed respectively. For intracellular stainings, cells were 
permeabilized, to enable monoclonal antibodies to enter the cell as well as the nucleus.  
Data obtained from Flow cytometry was analysed (e.g. compensation, gating analyses) with 
FlowJo software. Multiple cell parameters were identified using the Boolean gating approach 
and were further analysed with Simplified Presentation of Incredibly Complex Evaluations 
(SPICE) software.158 
 
3.3.4. In situ based imaging analysis 
 
The main focus of this thesis is the in situ characterization of immune cells present in the 
female genital mucosa. Hence, the microscopy based methods and imaging analysis will here 
be discussed in detail. 
While plenty of data describe the HIV-associated alterations of immune responses in blood, 
the immunity in mucosal compartments, including genital tissues have not been as 
extensively studied. The natural explanation is the logistic challenges of collecting such tissue 
samples from HIV-infected individuals, particularly those at high-risk of infection or from 
endemic areas.159 Genital tissue biopsies, similar in size to punch biopsies widely used in 
clinics, can be safely obtained from study participants, stored for years and not require 
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immediate processing. Microscopy-based in situ methods provide the fundamental approach 
to analyse properties of single cells in small tissue samples.  
Microscopy methods have a great visual advantage as compared to other cell based 
techniques. In situ based analysis of tissue samples allows evaluation of the exact anatomical 
cell localization, compartmentalization and distribution within the tissue. Furthermore, it 
allows the assessment of the spatial cell distribution and its proximity to other cells as well as 
pathogens, which is a crucial component of cell-mediated immunity.160 However, 
microscopy-based methods are associated with certain limitations. Poor antibody availability 
restricts the assessment of several markers at a time, resulting in the insufficient phenotypical 
and functional cell analysis. Moreover, evaluation of the specificity of immune cells is 
restricted by availability of specific reagents. For example, antigen-specific T cells can be 
identified with in situ MHC tetramer staining, which require significant expertise and 
reagents.161 However, the major limitation is the data acquisition and analysis. Manual cell 
counting is subjective, time consuming and particularly unsuitable for analysis of large scale 
samples. In contrast, automated cell counting gives higher precision, less variation and 
consumes less time. However, while the automated software are often insufficient when it 
comes to addressing inter-individual variation of biological material, manual specimen 
analysis performed by an expert may overcome this obstacle.  
In Paper III, we have used the automated image analysis software CellProfiler, which is a 
powerful tool for quantification of different immunological parameters in tissue sections.162-
164 CellProfiler was used to quantify fluorescently labelled cells expressing two surface 
markers (e.g. CD103+CD8+) in frozen ectocervical tissue sections (Figure 6). As compared to 
Paper I and Paper II, where cells were visualized with a peroxidase-labelled streptavidin-
biotin amplification method, in Paper III and Paper IV, immune cells were stained with 
fluorescently labelled antibodies. Immunofluorescent stainings allow the assessment of 
several markers on a single cell more precise as compared to immunohistochemical staining 
since specific excitation and emission wavelengths are used to visualize the fluorescently 
stained cells of interest.  
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Figure 6. In situ analysis of immunofluoresent staining with the image analysis software 
CellProfiler. The upper picture shows the input image with the manually outlined region of interest 
(ROI; white contour). The lower picture shows the segmentation result. Nuclei within the ROI are 
marked with a white outline; the positively stained cells are marked with red or green outlines and 
double positive cells with a yellow outline. 
 
3.4. Statistical analysis 
 
Assessment for normality showed a Non-Gaussian distribution of values for measured 
parameters.  
In Papers I, II and III the main objective was to assess the differences in HIV+FSW as 
compared to either HIV-FSW or HIV-LR control groups. Hence, between the two study 
groups, statistical significance between continues variables was assessed using the Mann-
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Whitney U test. Fisher’s exact test was used to evaluate categorical variables. Spearman’s 
rank correlation coefficient test was used to assess correlations.  
In Paper IV, statistical significance between continuous variables was assessed using the 
Mann-Whitney U test for comparisons of independent samples and the Wilcoxon signed rank 
test for paired samples. Furthermore, in order to assess the statistical differences between the 
three groups, multiple comparison analysis was performed with the use of the Kruskal-Wallis 
test, followed by post-hoc analysis. All calculations were performed using the Prism 5.00 
software and p-value of <0.05 was considered to be statistically significant. 
In the SPICE analysis performed in Papers III and IV, statistical comparisons between two 
or more groups were performed using permutation t-test.158 
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4 RESULTS AND DISCUSSION 
 
Cell-mediated immune responses have proven to be crucial for elimination of persistent 
infections, including HIV. Elucidation of these immune responses at the site of exposure and 
infection is thus necessary for the development of effective preventive and therapeutic 
interventions. In this thesis I have therefore quantified and characterized immune cells 
residing within the FGT mucosa, with the focus on CD8+ T cell subsets with potential 
effector capacity, in HIV-infected and uninfected women.  
Paper I. During HIV infection, massive CD4+ T cell depletion occurs at the mucosal sites, 
predominantly in the gastrointestinal mucosa. Moreover, HIV pathogenesis in the gut is 
associated with immune activation and inflammation that subsequently leads to the 
destruction of the gut epithelial barrier and subsequent translocation of microbial products 
into the circulation.52,165 Likewise, CD4+ T cell reduction as well as altered levels of other 
immune cells and increased immune activation has been observed in the FGT mucosa of 
HIV-infected women.29,166,167 However little is known about the expression of these cellular 
markers in the actual genital tissues. Thus, in this study we aimed to assess the expression of 
the HIV target cells (i.e. detecting the HIV-binding receptors CD4, CCR5, Langerin, DC-
SIGN and MR) as well as the immune activation status in the ectocervical tissues of HIV-
infected and uninfected women from the Kenyatta cohort. 
The protein expression of immune molecules was assessed by in situ staining and the mRNA 
expression by qPCR.  
The HIV-infected women reported to be infected for a median of 3 years and were ART-
naïve. We found that while these women had significantly lower CD4+ T cell blood cell 
counts, they had comparable levels of CD4 expression in their ectocervix, as compared to 
uninfected controls (Figure 7). This finding suggests that CD4+ cells in the cervix are not 
depleted to the same extent as previously observed in gut. However, the CD4 expression was 
visualized and analysed by single staining of CD4, which does not allow us to distinguish 
between the different cell populations expressing CD4 (i.e. mainly CD4+ T cells, dendritic 
cells and macrophages). It is thus possible that other CD4 expressing cells (DCs, 
macrophages) are altered in cervical mucosa. Further assessment of gene expression for 
macrophage (CD68) and DC (CD11c, CD1a) markers however showed comparable mRNA 
expression levels in HIV-infected and uninfected women, thus indicating that expression of 
these cells was not altered. Chronic HIV infection is associated with high CD4+ T cell 
turnover and regeneration of the CD4+ T cell compartment.27 It is thus plausible that the 
observed stable CD4+ expression is reflective of the “recovered” CD4+ T cell numbers during 
the chronic HIV phase. Furthermore, since HIV RNA was detected in the cervical tissues of 
these women (Paper II), one may speculate that the relative preservation of CD4+ cells may 
be involved in sustained levels of low viral replication. An interesting observation was that 
the HIV-FSW group displayed significantly lower CD4 expression in their cervix, compared 
to both HIV+FSW and HIV-LR groups. Whether, this low expression of CD4, the main HIV 
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receptor at the portal of HIV entry, contributes to the semi-resistant phenotype of these 
individuals is unclear and requires further investigations. 
 
 
Figure 7. CD4 expression in ectocervical tissues. The graph shows the distribution of A) RQ 
(Relative Quantification (UBC=1)) of CD4 mRNA expression levels and B) CD4 protein levels in 
ectocervical tissues from HIV+FSW, HIV-LR and HIV-FSW. Representative picture of 
immunohistochemical staining showing CD4 in brown and hematoxylin in blue in the ectocervical 
tissues from C) HIV+FSW, D) HIV-LR and E) HIV+FSW. Reprinted with permission.68 Copyright 
2013. The American Association of Immunologists, Inc. 
 
Moreover, the HIV-infected women had elevated levels of the HIV receptor molecules 
CCR5, Langerin, DC-SIGN, and MR, which may reflect pathogen-induced proinflamatory 
responses and influx of immune cells. In consistence with previous observations,168 elevated 
levels of proinflammatory cytokines, including IFN-, TNF, IL-17 and IL-6, were here 
observed in the cervix of HIV-infected women (Figure 8). The inflammatory environment in 
the lower FGT may thus promote viral replication and genital shedding, which may 
subsequently increase the risk of sexual HIV transmission. 
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Figure 8. Quantification of cytokines. The graph shows the distribution of RQ (Relative 
Quantification (UBC=1)) of mRNA expression levels of cytokines in the ectocervical tissues from 
HIV+FSW (red), HIV-LR (green) and HIV-FSW (blue). Reprinted with permission.68 Copyright 2013. 
The American Association of Immunologists, Inc.  
 
Paper II. CD8+ T cell responses have been shown to play an essential role in controlling HIV 
infection.128 However, few studies have interrogated these cells in the genital tissues, the 
main portal of HIV entry and the main replication site before the virus spread to lymph nodes 
and circulation.64,101,169 Cervical CD8+ T cell responses have been primarily assessed in 
cervical MNCs obtained from HIV-infected women.138,166,168 However, localization and 
spatial distribution of CD8+ T cells and their proximity to other cells within the tissues 
determines the efficiency of cell-mediated immune responses. Therefore, the main aim of this 
study was to enumerate and characterize CD8+ T cells and to discriminate the epithelial and 
submucosal distribution of these cells within the cervix of HIV-infected and uninfected 
women from the Kenyatta cohort. Thus, cell markers, including CD8, CD3 and HLA-DR, 
were assessed by in situ staining and by qPCR. HIV RNA expression in tissue was measured 
by in situ hybridization, while viral load in plasma and CSV (viral shedding) was measured 
by qPCR. 
We found that, as compared to uninfected controls, HIV-infected women had significantly 
higher amounts of total cells, including CD3+, CD8+ and HLA-DR+ cells in both the epithelial 
and the submucosal compartments of the ectocervix. However this difference was more 
pronounced in the epithelial compartment. To investigate if these CD8+ cells were T cells, we 
next performed fluorescent double staining and observed that the majority of CD8 expressing 
cells indeed were T cells (Figure 9). The elevated levels of cervical CD8+ T cells in HIV-
infected women observed here are in line with previous findings from cervical MNCs.166,168  
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Figure 9. Enumeration and visualization of CD8+ cells. A) The graph shows the distribution and 
median of the percentage of CD8+ cells out of total tissue area in the epithelial and submucosal 
compartments of the ectocervix. B) Representative picture illustrating in situ staining of CD8+ cells 
(red) and CD3+ (green) in the ectocervical tissue from HIV+FSW. Double positive CD8+ T cells are 
shown in yellow. Reprinted with permission.170 Copyright 2014. The American Association of 
Immunologists, Inc.  
 
We could furthermore detect HIV RNA+ cells in the cervix of four out of the twenty HIV-
infected women (Figure 10). Interestingly, two out of those four had low/undetectable 
plasma viral load (40 and 20 HIV RNA copies/ml, respectively) and undetectable viral 
shedding (>20 HIV RNA copies/ml). This indicates that virus levels in the genital tissues 
cannot be fully predicted by the virus levels present in circulation or in the vaginal secretions. 
Studies using NHP that were intravaginally infected with SIV have shown that SIV infection 
in the genital tract is highly focal, and small founder populations of infected cells (SIV RNA+ 
cells) are disperse in the FGT tissues.80,81 In our study, HIV RNA detection was performed in 
three tissues sections per individual, from 3 mm2 ectocervical biopsy. It is thus possible that 
our results are underestimating the total levels of HIV replication in the FGT of these women, 
suggesting that the FGT should not be neglected as a potential viral reservoir. 
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Figure 10. HIV RNA+ cells present in ectocervical tissue. Detection of HIV RNA+ cells (green 
silver grains indicated by the black arrows) with in situ hybridization in the ectocervical tissue from 
HIV+FSW. Reprinted with permission.170 Copyright 2014. The American Association of 
Immunologists, Inc. 
 
Furthermore, we found that the numbers of cervical CD8+ cells were the only immune marker 
that significantly correlated with plasma and cervical viral load, but not with the presence of 
HIV RNA, indicating the importance of CD8+ cells in the local HIV pathogenesis. We also 
assessed the levels of cellular immune activation in the cervix using HLA-DR expression as a 
surrogate marker for immune activation.37 The HIV-infected women displayed elevated 
levels of HLA-DR, which furthermore correlated with the CD8 expression in their cervix. 
The higher levels of cellular activation observed here within the HIV-infected group are in 
line with our previous findings (Paper I). Additionally, we observed that CD8 expression 
significantly correlated with CD69 expression in cervix of these HIV-infected women. CD69 
expression on tissue-derived cells is associated with their tissue-residing, non-circulating 
phenotype.147 This suggests that CD8+ T cells present in the cervix of HIV-infected women 
may display a tissue-residing phenotype and requires further investigations. 
Overall, our data indicates that, local immune activation and viral shedding are associated 
with increased levels of CD8+ T cells in genital mucosa. Future investigations are thus 
required to scrutinize the functional phenotypes of these CD8+ T cells and their role in the 
local HIV pathogenesis in genital tissues.  
Paper III. In Paper II we hypothesised that cervical CD8+ T cells, particularly those 
localized in the epithelium displayed a tissue-residing phenotype. Thus, in study III we 
wanted to investigate if these cervical CD8+ T cells expressed CD103 and displayed a tissue- 
resident phenotype. Furthermore, we aimed to investigate if there was an association between 
tissues residing and circulating CD8+CD103+ T cells as previously seen,171 and if the 
numbers or phenotype of these cells were altered in HIV-infected versus uninfected women. 
In situ staining was thus performed to enumerate CD8+ TRM cells (i.e. CD8
+CD103+ cells 
localized within the cervical epithelium) and flow cytometry was used to characterize CD103 
expressing CD8+ T cells in paired ectocervical biopsies and blood samples respectively, from 
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HIV-infected and uninfected women from the Kenyatta cohort. Furthermore, CD8+ TRM 
phenotype was assessed by flow cytometry and in situ stainings in the cervical tissue samples 
obtained from women from the St. Göran cohort.  
We observed that CD103+CD8+ T cell frequencies were significantly reduced in blood 
of HIV-infected women, as compared to uninfected controls. Circulating CD103+CD8+ T 
cells were enriched within the effector memory pool in HIV-infected women, however the 
majority of these cells displayed a transitional memory phenotype in all groups analysed. 
Furthermore, the CD103+CD8+ T cell population seems to be highly activated in chronic HIV 
infection, but not exhausted compared to the total CD8+ T cell pool.  
Next, we investigated if the cervical CD8+ TRM cells were altered during HIV infection. We 
observed that the total numbers of CD8+ TRM cells per tissue area as well as frequencies of 
CD8+ TRM cells out of total cells were significantly increased in the ectocervix of HIV-
infected women as compared to uninfected women. However, the proportion of CD8+ TRM 
cells out of total CD8+ cells was significantly reduced in HIV-infected women (Figure 11). 
 
 
 
 
Figure 11. CD8+ TRM cells in ectocervical epithelium. Quantification of CD103+CD8+ (CD8+ TRM) 
cells in the ectocervical epithelium. The graphs show the distribution and median of A) the number of 
CD8+ TRM cells per tissues area (100µm2), B) the % of CD8+ TRM out of total cells and C) the % of 
CD8+ TRM cells out of total CD8+ cells in the ectocervical tissues from HIV+FSW, HIV-FSW and HIV-
LR. 
 
One may speculate, that upon chronic HIV infection and persistent STIs and HIV-exposure 
during active sex work, CD8+ T cells, including CD8+ TRM cells, may be actively recruited 
to/or expanded in genital mucosa. 
On the other hand, the decrease in the proportion of cervical epithelial CD8+ TRM cells out of 
total CD8+ T cells may be due to the observed infiltration/expansion of CD103-CD8+ cells in 
the cervical epithelium of HIV-infected women. These CD103-CD8+ cells were mainly 
observed in close proximity to the ectocervical basal membrane. It is possible that the CD103- 
cells migrate further up in the epithelium, upregulate CD103 via interaction with E-cadherin 
and acquire a bona fide TRM phenotype. Watanabe and colleagues have recently showed that 
in human skin, CD103- T cells also represent a non-circulating TRM phenotype, however with 
less effector capacity as compared to CD103+ TRMs.147 Decreased frequencies of CD103 
expressing CD8+ T cells and redistribution of E-cadherin have been observed in gut of HIV-
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infected individuals.51,172 This suggests, that upon HIV infection, impaired tissue retention 
mechanisms may subsequently alter local CD8+ T cell-mediated immune surveillance. 
Therefore it is possible that CD103-CD8+ T cells in cervix may display an altered phenotype 
as compared to those expressing CD103. However, these questions could not be addressed in 
this cross-sectional study and further investigations of in vivo T cell dynamics and migration 
patterns are thus required. 
Furthermore, we did not find a significant correlation between the frequencies of circulating 
and cervical CD103+ cells among the CD8+ T cell population as previously seen by Kiravu et 
al.171 This discrepancy may be due to differences in the techniques used as well as the source 
of the samples analysed. Thus, further studies are warranted to interrogate the association 
between tissues residing and circulating CD8+CD103+ T cells. 
Nevertheless, our data further provides a valid insight in the distribution of tissue residing 
CD8+ T cells, which may have a potential capacity to eliminate incoming pathogens, such as 
HIV in the genital mucosa.  
Paper IV. MAIT cells are a recently described subset of invariant T cells that are restricted 
by MHC class I-related MR1 molecule.105,106,112 Several studies indicate that MAIT cells 
display broad antimicrobial capacity by production of proinflammatory cytokines and direct 
killing of bacterially infected cells.107,116,118 While MAIT cells have been detected in various 
mucosal tissues,107 their presence in the genital mucosa has not been investigated. Hence, in 
the present study, we wanted to characterize MAIT cells in the FGT tissues of healthy women 
and assess their phenotypic and functional properties in comparison to circulating MAIT 
cells. Thus, the distribution of MAIT cells within the FGT was assessed by in situ staining, 
and flow cytometry was used to enumerate as well as to phenotypically and functionally 
characterize MAIT cells in the FGT tissues obtained from healthy Swedish women included 
in the St. Göran cohort as well as in PBMC samples obtained from age-matched healthy 
Swedish women. 
MAIT cells and MR1+ APCs were present in the upper and lower FGT, with their 
pronounced localization within clusters of IL-18α+ cells in the ectocervical epithelium. 
Preferential MAIT cell localization within the ectocervix may have a functional purpose, 
since the lower FGT is highly exposed to both pathogenic and commensal microbes. We 
furthermore characterized the phenotype and functional profile of MAIT cells present in the 
FGT and compared it with blood-derived MAIT cells. While the phenotype of MAIT cells 
from the FGT and blood was comparable (IL-18Rα+, CD127+, α4β7+, PD-1+, PLZF+, 
RORγt+, Helios+, Eomes+, T-bet+), their functional profile was different. Namely, stimulation 
with E.coli showed that MAIT cells from the FGT were biased towards IL-17 and IL-22 
production, while blood-derived MAIT cells were more prone to produce IFN-, TNF and 
GrzB (Figure 12). Deeper analysis revealed that the polyfunctional profile of MAIT cells 
from the FGT and blood was also skewed towards Th1/Th17 and Th1 cytokine responses, 
respectively. The preferential IL-17 and IL-22 production by FGT-derived MAIT cells is 
intriguing, considering that these cytokines are essential for both antimicrobial responses and 
maintenance of mucosal barrier integrity.173,174 It is likely that production of these cytokines 
is modulated by the local cytokine environment, local microflora and possibly 
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transcriptionally regulated as it has been shown in murine MAIT cells.175 Furthermore, the 
preferential IL-17/IL-22 production seen in the FGT as compared to blood was not limited to 
MAIT cells since other immune cells within the FGT also produced these cytokines.  
Our data indicates that FGT-derived MAIT cells respond to bacterial stimuli in a fashion 
unique to FGT. In virtue of their polyfunctionality and preferential IL-17/IL-22 production, 
MAIT cells may act as first line of defence against incoming pathogens as well as keepers 
of mucosal homeostasis and barrier integrity in the genital mucosa. 
 
 
Figure 12. MAIT cells in the FGT and blood. A) Representative picture of immunofluorescent 
staining of Vα7.2+ (red) and IL-18Rα+ (green) cells in the ectocervical tissue from healthy women. 
Double positive MAIT cells are indicated with white arrows. DAPI (blue) was used as a 
counterstain for visualization of cell nuclei. B) The graphs show the distribution and median of 
cytokine and GrzB production by FGT- and blood-derived MAIT cells, assessed by flow cytometry.  
 
Moreover, the presence of IL-17 and IL-22 producing MAIT cells at the portal of HIV entry 
and replication site is intriguing, since a severely compromised mucosal barrier is a hallmark 
of HIV infection.52,165 Little is known about MAIT cells in HIV pathogenesis, except that 
these cells are not preferentially infected by HIV.121 However, levels of MAIT cells are 
reduced in blood and relatively preserved in mucosal compartments of HIV-infected 
individuals, suggesting that circulating MAIT cells may be recruited to the barrier tissues for 
preservation of mucosal barrier integrity.120,121 Given the early depletion of cervical Th17 
cells, it is tempting to speculate that the presence of IL-17/IL-22 producing MAIT cells in the 
genital mucosa would play an important role for the preservation of the barrier integrity and 
subsequent prevention of the dissemination of local infections. Thus, further investigations 
are warranted to interrogate the role of MAIT cells in genital mucosa upon HIV infection.
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
During the 30 years of the HIV epidemic different vaccination approaches have been tested 
and all failed to achieve levels of protection that would be needed for clinical efficacy in a 
global perspective.176 Even today, a development of an effective HIV vaccine remains to be 
elusive. On the other hand, preventive interventions including PrEP (up to 90 % protection 
in different cohorts), male circumcision (up to 60% protection) and antiviral drug 
administration with topical gels (CAPRISA, >50% protection in high adherers) or vaginal 
ring (Vaginal ring with Dapivirine, 37% protection) have shown better protection against 
HIV infection than the most successful HIV vaccine trial RV144 (31% protection).177-181 
Despite the high effectiveness of PrEP, treatment based eradication of the HIV epidemic is 
not economically or logistically feasible. Hence other implementations of preventive 
measures to stop sexual HIV transmission/acquisition at the site of exposure (genital mucosa) 
before establishment of systemic infection are also needed and may provide an effective 
approach to end the HIV epidemic. 
As discussed above, the initial HIV transmission across the female genital mucosa is 
associated with a great vulnerability of the virus and may thus provide a “window of 
opportunity” for preventive interventions. However, lack of understanding of immune 
correlates of HIV protection at the portal of entry makes it difficult to formulate what kind of 
immune responses would be desirable to achieve. Furthermore, limited availability of genital 
tissue samples obtained from individuals infected with or exposed to HIV hamper the 
analysis of these responses. Therefore in this thesis we aimed to characterize cervical immune 
cells in a unique set of samples obtained from HIV-seropositive and seronegative FSW, at 
high risk of HIV infection, and lower risk women from the same geographical area.  
In Paper I and II we report that HIV-infected women display high immune activation 
together with ongoing viral replication in their cervix that may subsequently lead to increased 
HIV transmission. Thus, high levels of immune activation and active viral replication may 
contribute to altered barrier integrity of the genital mucosa, as previously shown in gut 
tissues, which can subsequently lead to dissemination of local infections.50,165 Furthermore, 
we also observe that the HIV-infected women had comparable levels of CD4 expression in 
their ectocervix, as compared to uninfected controls. Interestingly, decreased numbers of 
CD4+ cells were observed in cervix of HIV-seronegative FSW, who display a semi-resistant 
to HIV infection. Taken together, this suggests, that low levels of HIV target cells and low 
local immune activation in genital mucosa are crucial parameters for reduced HIV acquisition 
and thus have to be considered in mucosal vaccination strategies.  
In Papers II and III we show that HIV–infected women display elevated levels of cervical 
CD8+ cells, particularly those present in the epithelium (CD8+ TRM). Elevated numbers of 
cervical CD8+ T cells implicate that they play an important role in local viral pathogenesis. 
We have not assessed the functionality and specificity of these cells in the cervix of HIV-
infected women and uninfected controls. It would thus be interesting to investigate whether 
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these CD8+ T cells are beneficial for control of HIV replication and to scrutinize the 
phenotypic and functional alterations of these cells in HIV infection. 
In SIV-infected NHP CD8+ T cell responses are characterized as “too little too late”, meaning 
that too little anti-viral responses occurs too late at the initial site of HIV infection, after the 
peak of viral replication.182 This suggests that optimal protection may be achieved by potent 
effector responses elicited at the site of exposure/initial replication, exploiting the window of 
viral vulnerability.152 Different studies have shown that a high magnitude of antigen-specific 
CD8+ T cell responses can indeed be induced and maintained at the portal of entry. However, 
the majority of these vaccination approaches have been studied in murine models and have to 
be further evaluated in humans. Intranasal immunisation has shown to prime long-lived HSV-
2-specific CTL responses in genital-associated lymphoid tissues.183 Furthermore, intravaginal 
prime-boost immunisation elicited potent genital CD8+ T cell responses against HSV-2 and 
HIV.184,185 Shin and colleagues have exploited a “pull and prime” vaccination approach, by 
first systemically priming CD8+ T cell responses and then initiating recruitment of these cells 
to the genital tissues. Importantly, pull and prime vaccination strategy did not result in either 
elevated levels of genital CD4+ T cells or mucosal inflammation.150  
In Paper IV, we showed that polyfunctional, IL-17/IL-22 biased MAIT cells are present in 
the FGT mucosa of healthy women. It is tempting to speculate that antimicrobial MAIT cells, 
at the portal of HIV entry, may be important for the preservation of the genital barrier 
integrity and act as a first line of defence against invading pathogens. Moreover, FGT-derived 
MAIT cells displayed a unique functional phenotype, distinct from circulating counterparts. 
This highlights the uniqueness of the FGT environment, indicating that systemic responses 
cannot be used as a general marker of the immunological environment.  
We hypothesise that the presence of effector immune cells at the portal of HIV entry would 
be beneficial for the viral control at the initial phase of viral transmission. Hence, vaccine-
induced potent cell-mediated immune responses could potentially eliminate founder HIV 
populations before viral dissemination to lymphoid tissues and establishment of systemic 
infection. Thus, studies described here may contribute to the knowledge needed for the 
development of better vaccination and/or microbicide strategies against HIV and other 
sexually transmitted infections. 
Nevertheless, the HIV epidemic does not happen in a laboratory environment and therefore 
all potential intervention strategies must be implemented considering affected populations. In 
2010, speaking about HIV, Michel Sidibé, Executive Director of UNAIDS said, “This 
epidemic unfortunately remains an epidemic of women”. In 2015, the majority of new 
adolescent infections globally were still represented by young women. This “feminization” of 
the HIV epidemic is particularly pronounced in Sub-Saharan Africa and can be associated 
with various social and cultural factors. Women experience more violence in their 
relationships, which together with their lower socioeconomic status lead to power imbalance. 
In these relationships, women cannot take their own decisions about safer sexual practices, 
including use of contraception.186 From this perspective, implementation of antiviral drug 
administration with topical gels or vaginal rings is very valuable and benefits women of 
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taking their own preventive measures. Furthermore, FSW is a key population where the HIV 
prevalence is twelve times higher compared to the general population.  
HIV transmission in women is very complex, since it affects not only their sexual partners 
but also their children. That being said, effective protection of women would have a great 
impact on the general HIV epidemic and hence should be considered a high priority globally. 
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